FDA Accelerated Approval and Breakthrough Therapy Pathways

Two of the FDA's most consequential regulatory mechanisms — Accelerated Approval and Breakthrough Therapy designation — compress the timeline between drug discovery and patient access for serious or life-threatening conditions. This page covers how each pathway is defined under federal statute and regulation, the procedural mechanics that distinguish them, the clinical scenarios in which sponsors seek them, and the decision boundaries that determine eligibility and post-market obligations. Both pathways interact with the broader FDA drug approval process and carry distinct evidentiary requirements that shape how sponsors design trials and submit applications.

Definition and Scope

Accelerated Approval is a regulatory pathway codified at 21 U.S.C. § 356(c) and implemented through 21 C.F.R. Part 314, Subpart H (drugs) and 21 C.F.R. Part 601, Subpart E (biologics). It allows FDA approval based on a surrogate endpoint — or an intermediate clinical endpoint — reasonably likely to predict clinical benefit, rather than requiring demonstration of direct clinical benefit before market entry. Post-market confirmatory trials are required to verify the predicted benefit. The 2022 Food and Drug Omnibus Reform Act (FDORA), signed into law as part of the Consolidated Appropriations Act of 2023, substantially strengthened FDA's authority to require and enforce those confirmatory trials, including the power to withdraw approval if trials are not conducted with due diligence (FDA FDORA Summary).

Breakthrough Therapy designation is authorized under 21 U.S.C. § 356(a) and was established by the FDA Safety and Innovation Act (FDASIA) of 2012. It applies to drugs intended to treat a serious condition where preliminary clinical evidence indicates the drug may demonstrate substantial improvement on at least one clinically significant endpoint over available therapy. As of FDA reporting through 2022, the agency had granted more than 300 Breakthrough Therapy designations since the program's inception (FDA Breakthrough Therapy).

These two pathways are distinct but frequently combined: a drug may hold Breakthrough Therapy designation and simultaneously pursue Accelerated Approval, stacking the procedural benefits of each.

How It Works

Accelerated Approval — procedural sequence:

1. Sponsor identifies a surrogate or intermediate endpoint with scientific support for its predictive value.
2. Sponsor submits a New Drug Application (NDA) or Biologics License Application (BLA) referencing that endpoint as the basis for approval.
3. FDA evaluates whether the endpoint is "reasonably likely to predict" clinical benefit — a lower evidentiary bar than demonstrated benefit.
4. Upon approval, FDA requires post-market confirmatory trials under a binding agreement specifying milestones and timelines.
5. If confirmatory trials fail or are not completed with due diligence, FDA may initiate expedited withdrawal procedures under FDORA authorities.

Breakthrough Therapy designation — procedural sequence:

1. Sponsor submits a designation request any time before NDA/BLA submission, typically early in Phase 2.
2. FDA must respond within 60 days of receipt (21 U.S.C. § 356(a)(3)).
3. Upon designation, FDA commits to intensive guidance, including senior agency staff involvement, rolling review of completed study sections, and organizational commitment to meet with the sponsor more frequently than standard review schedules.
4. Designation does not guarantee approval; it reorganizes FDA's internal resource allocation toward the program.

The critical distinction: Accelerated Approval is an approval standard (what evidence suffices); Breakthrough Therapy is a procedural designation (how FDA engages with the sponsor). A drug can receive one without the other.

Common Scenarios

Oncology represents the most concentrated application of Accelerated Approval. FDA has used the pathway for therapies in hematologic malignancies, solid tumors, and rare cancers where overall survival data would take years to accumulate. Tumor response rate and progression-free survival serve as common surrogate endpoints in this context.

Rare diseases and orphan conditions frequently combine FDA orphan drug designation with Breakthrough Therapy and Accelerated Approval simultaneously. The three designations operate in parallel without conflict, each adding independent procedural or commercial benefits.

Infectious disease, particularly HIV and hepatitis C, established early precedents for surrogate endpoint use — CD4 count and viral load, respectively — that later anchored the modern Accelerated Approval framework.

Neurological and psychiatric conditions present more contested scenarios. Surrogate endpoints in Alzheimer's disease, for example, have been subject to scientific dispute about their predictive value for clinical outcomes, generating public comment and advisory committee review.

Decision Boundaries

The key decision points that separate these pathways from standard review include:

A sponsor's decision to pursue Accelerated Approval hinges on whether a validated or widely-accepted surrogate endpoint exists. If none exists, FDA's Division of Drug Information and the relevant therapeutic review division must be consulted before trial design is locked. Breakthrough Therapy designation turns on the phrase "substantial improvement" — FDA interprets this as a large effect size, not marginal differentiation, supported by data from at least one Phase 1 or Phase 2 trial.

Both pathways intersect with FDA clinical trials oversight requirements, since trial design choices made early in development determine whether surrogate endpoint data will be sufficient and whether the preliminary evidence threshold for Breakthrough Therapy can be met. Sponsors navigating either pathway should also review applicable FDA new drug application submission standards, as the approval pathway affects the structure and content of the marketing application itself. The full landscape of FDA regulatory pathways is mapped at fdaauthority.com.